These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 4089794)

  • 1. Heparin response and clearance in acute and chronic liver disease.
    Sette H; Hughes RD; Langley PG; Gimson AE; Williams R
    Thromb Haemost; 1985 Oct; 54(3):591-4. PubMed ID: 4089794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure.
    Langley PG; Keays R; Hughes RD; Forbes A; Delvos U; Williams R
    Hepatology; 1991 Aug; 14(2):251-6. PubMed ID: 1860682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD163 in patients with liver diseases: very high levels of soluble CD163 in patients with fulminant hepatic failure.
    Hiraoka A; Horiike N; Akbar SM; Michitaka K; Matsuyama T; Onji M
    J Gastroenterol; 2005 Jan; 40(1):52-6. PubMed ID: 15692789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyramine kinetics and metabolism in cirrhosis.
    Faraj BA; Fulenwider JT; Rypins EB; Nordlinger B; Ivey GL; Jansen RD; Ali FM; Camp VM; Kutner M; Schmidt F; Rudman D
    J Clin Invest; 1979 Aug; 64(2):413-20. PubMed ID: 457860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biliary excretion of mezlocillin in patients with hepatic disease.
    Hildebrandt R; Gundert-Remy U; Raedsch R; Sieg A; Stiehl A
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):384-7. PubMed ID: 7582392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology.
    Joeres R; Brachtel D; Gallenkamp H; Hofstetter G; Klinker H; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():56-61. PubMed ID: 7483716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hepatic clearance of 99mTc-p-butyl HIDA in liver diseases. Correlations with routine hematochemical parameters of liver function].
    Custro N; De Francisci MC; Patanella I; Scafidi V; Indovina I
    Minerva Med; 1984 Nov; 75(42):2527-32. PubMed ID: 6083507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute phase response after liver transplantation for fulminant hepatic failure and cirrhosis.
    Izumi S; Hughes RD; Langley PG; Pernambuco JR; Williams R
    Transpl Int; 1995; 8(5):340-5. PubMed ID: 7576014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of trapidil (Rocornal) in patients with chronic liver disease.
    Berndt A; Pönicke K; Weiss M
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):492-3. PubMed ID: 1490801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S-100b and neuron-specific enolase in patients with fulminant hepatic failure.
    Strauss GI; Christiansen M; Møller K; Clemmesen JO; Larsen FS; Knudsen GM
    Liver Transpl; 2001 Nov; 7(11):964-70. PubMed ID: 11699032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of continuous low-dose intravenous heparin administered during operation on postoperative measurements of antithrombin III and antifactor Xa.
    Jennings SA; Heather BP; Greenhalgh RM
    Surgery; 1984 Sep; 96(3):550-5. PubMed ID: 6474360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporation of precursors into sterols and proteins in liver biopsies from patients with liver disorders.
    Evensen SA; Ritland S; Elgjo K; Solberg HE; Skrede S
    Scand J Gastroenterol; 1984 Jan; 19(1):6-13. PubMed ID: 6143395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
    Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
    Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasma clearance of cholic acid in patients with chronic diseases of the liver].
    Medrzejewski W; Habior A; Samociuk-Medrzejewska B; Cwikła M
    Pol Tyg Lek; 1990 Apr 16-30; 45(16-18):335-7. PubMed ID: 2235721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of various types of liver diseases on the behavior of cefoperazone].
    Malè PJ; Dayer P; Châtelain G; Rudhardt M; Fabre J
    Schweiz Med Wochenschr; 1983 Dec; 113(49):1860-3. PubMed ID: 6676938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum leptin levels in patients with nonalcoholic chronic liver disease.
    Nakamuta M; Tada S; Uchimura K; Enjoji M; Kinukawa N; Iwamoto H; Sugimoto R; Shimada M; Ohashi M; Sugimachi K; Nawata H
    Hepatogastroenterology; 2001; 48(38):527-32. PubMed ID: 11379347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin elimination in patients with liver cirrhosis.
    Teien AN
    Thromb Haemost; 1977 Oct; 38(3):701-6. PubMed ID: 579516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of benzoate-metabolizing capacity in patients with chronic liver disease: pharmacokinetic analysis.
    Yamada S; Yamamoto T; Suou T; Fujii T; Takayama M; Amisaki T; Tabuchi F; Kobayashi J; Hasegawa M; Hoshino U
    Res Commun Chem Pathol Pharmacol; 1992 Apr; 76(1):53-62. PubMed ID: 1518961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation.
    Nankervis CA; Preston TJ; Dysart KC; Wilkinson WD; Chicoine LG; Welty SE; Nelin LD
    ASAIO J; 2007; 53(1):111-4. PubMed ID: 17237658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.